Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilars Create Class-wide Competition, German Experience Finds

Executive Summary

Follow-on biologics may be able to achieve broader market penetration if they are not deemed to be interchangeable or substitutable for a single reference product, according to Novartis

You may also be interested in...

New Brand, Same MS Drug: Novartis Launches Extavia In Europe

Novartis lays foundation for potential MS platform with European launch of its own branded version of Bayer-Schering’s Betaferon (interferon beta-1b).

Biosimilar Competition Debate: Must Products Be Interchangable To Generate Savings?

FTC hears arguments on whether the number of competitors, or their pharmacy-level substitutability, drives prices lower.

Biosimilars Should Face Patent Challenges Only After Approval, Novartis Says

Linking patent disputes to regulatory approval of follow-on biologics would provide no competitive benefit for patients and could discourage innovation, contends Robert Pelzer, head of Novartis' North American operations

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts